From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt
-
Published:2024-07-03
Issue:7
Volume:17
Page:881
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Elgarhy Fadya M.12ORCID, Borham Abdallah1ORCID, Alziny Noha1ORCID, AbdElaal Khlood R.3ORCID, Shuaib Mahmoud1, Musaibah Abobaker Salem1ORCID, Hussein Mohamed Ali1ORCID, Abdelnaser Anwar1ORCID
Affiliation:
1. Institute of Global Health and Human Ecology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt 2. Egypt Center for Research and Regenerative Medicine (ECRRM), Cairo 4435121, Egypt 3. Graduate Program of Biotechnology, School of Sciences and Engineering, The American University, Cairo 11835, Egypt
Abstract
Pharmacogenomics (PGx) is the hope for the full optimization of drug therapy while minimizing the accompanying adverse drug events that cost billions of dollars annually. Since years before the century, it has been known that inter-individual variations contribute to differences in specific drug responses. It is the bridge to what is well-known today as “personalized medicine”. Addressing the drug’s pharmacokinetics and pharmacodynamics is one of the features of this science, owing to patient characteristics that vary on so many occasions. Mainly in the liver parenchymal cells, intricate interactions between the drug molecules and enzymes family of so-called “Cytochrome P450” occur which hugely affects how the body will react to the drug in terms of metabolism, efficacy, and safety. Single nucleotide polymorphisms, once validated for a transparent and credible clinical utility, can be used to guide and ensure the succession of the pharmacotherapy plan. Novel tools of pharmacoeconomics science are utilized extensively to assess cost-effective pharmacogenes preceding the translation to the bedside. Drug development and discovery incorporate a drug-gene perspective and save more resources. Regulations and laws shaping the clinical PGx practice can be misconceived; however, these pre-/post approval processes ensure the product’s safety and efficacy. National and international regulatory agencies seek guidance on maintaining conduct in PGx practice. In this patient-centric era, social and legal considerations manifest in a way that makes them unavoidable, involving patients and other stakeholders in a deliberate journey toward utmost patient well-being. In this comprehensive review, we contemporarily addressed the scientific leaps in PGx, along with various challenges that face the proper implementation of personalized medicine in Egypt. These informative insights were drawn to serve what the Egyptian population, in particular, would benefit from in terms of knowledge and know-how while maintaining the latest global trends. Moreover, this review is the first to discuss various modalities and challenges faced in Egypt regarding PGx, which we believe could be used as a pilot piece of literature for future studies locally, regionally, and internationally.
Reference110 articles.
1. Khasawneh, L.Q., Al-Mahayri, Z.N., and Ali, B.R. (2022). Mendelian Randomization in Pharmacogenomics: The Unforeseen Potentials. Biomed. Pharmacother., 150. 2. Pharmacogenetics of antidepressants (from history to the present);Ilyina;Vestn. Nevrol. Psihiatr. Nejrohir. Bull. Neurol. Psychiatry Neurosurg.,2021 3. Polymorphisms at CYP Enzymes, NR1I2 and NR1I3 in Association with Virologic Response to Antiretroviral Therapy in Brazilian HIV-Positive Individuals;Espasandin;Pharm. J.,2022 4. Malsagova, K.A., Butkova, T.V., Kopylov, A.T., Izotov, A.A., Potoldykova, N.V., Enikeev, D.V., Grigoryan, V., Tarasov, A., Stepanov, A.A., and Kaysheva, A.L. (2020). Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization. Pharmaceutics, 12. 5. Primorac, D., Höppner, W., and Bach-Rojecky, L. (2023). Pharmacogenomics of Drug-Metabolizing Enzymes. Pharmacogenomics in Clinical Practice, Springer International Publishing.
|
|